Retrospective study on the prevalence of COVID-19 confirmed cases and evidence of gender bias in Libya

Sammendrag

Introduction. To stop SARS-CoV-2 from spreading, it's crucial to have a solid understanding of the baseline characteristics of demographic variables, clinical symptoms, and comorbidity so that quarantining and testing protocols can be developed.

Material and methods. A retrospective study was conducted on COVID-19 Laboratory confirmed cases. Data were collected by using kobo toolbox, demographic variables, clinical symptoms, and Comorbidity was considered. Yates-corrected chi2 tests and Multinomial Logistic Regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) of factors and their impact on COVID-19 prevalence.

Results. A total of 6302 of which 3536(56.1%) men and 2766 (44%) women with a mean age (±SD) of 44±17.6 years were included within the study.  Clinical symptoms and Comorbidity were significant for both sexes p<0.0001. Multinomial Logistic Regression confirmed that age <55, 3 or more symptoms (OR=1.130 CI95% 1.013-1.261) and 3 or more comorbidities (OR=1.035 Cl95% 0.942-1.137) were a significant risk factor for COVID-19 prevalence in male patients, among women, age 85>/=, 3 or more symptoms (p<0.0001, OR=1.995 CI95% 1.335-2.992) and 3 or more comorbidities (p<0.0001, OR=1.538 Cl95% 1.045-2.640) were significant risk factor for COVID-19 prevalence in females.

Conclusions. Our study suggests that the prevalence of COVID-19 patients and symptoms was higher in men than women. The high prevalence of smoking could have contributed to the high prevalence of COVID-19 among men. Study also suggests that the presence of at least one or combined comorbidities are risk factors of COVID-19 prevalence and a potential risk factor COVID-19 - related outcomes. More efforts should be exercised to protect patients with one or more comorbidities from being exposed to infection.

pdf (English)

|Utsikt: 487| |pdf (English) Nedlastinger: 215|


pdf (English)
##submission.license.cc.by4.footer##

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370